Related Experiment Video

Updated: May 24, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions

Peter M Ellis1, Khalid Al-Saleh

  • 1Juravinski Cancer Centre, Hamilton, Ontario, Canada. peter.ellis@jcc.hhsc.ca

Critical Reviews in Oncology/Hematology
|March 13, 2012
PubMed

Insights

Anti-angiogenesis therapies targeting vascular endothelial growth factor (VEGF) show promise for non-small cell lung cancer (NSCLC). Further research into triple angiokinase inhibitors and biomarkers is needed for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecularly targeted therapies are crucial for treating cancer due to a better understanding of cell growth abnormalities.
  • Angiogenesis, the formation of new blood vessels, is a key target for non-small cell lung cancer (NSCLC) treatment.
  • Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is an approved therapy for NSCLC.

Purpose of the Study:

  • To review current anti-angiogenic agents under development for NSCLC.
  • To explore the potential of triple angiokinase inhibitors in improving therapeutic outcomes for NSCLC patients.
  • To highlight the need for biomarkers to guide patient selection for anti-angiogenesis therapy.

Main Methods:

  • Review of various anti-angiogenic agents targeting VEGF, platelet-derived growth factor (PDGF), and fibroblast-derived growth factor (FGF).
  • Analysis of clinical outcomes for these agents in combination with chemotherapy for advanced NSCLC.
  • Discussion of the role of triple angiokinase inhibitors and biomarker identification.

Main Results:

  • Several agents inhibiting VEGF, PDGF, and/or FGF are under development.
  • Currently, no single-target or dual-target anti-angiogenic agents combined with chemotherapy have improved overall survival in advanced NSCLC.
  • Triple angiokinase inhibitors show potential for improved therapeutic outcomes.

Conclusions:

  • Anti-angiogenesis therapy is a promising strategy for NSCLC.
  • Triple angiokinase inhibitors represent a potential advancement in NSCLC treatment.
  • Biomarker identification is essential for optimizing patient selection and maximizing the benefit of anti-angiogenesis therapies in NSCLC.

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...